Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5834025A · kind A · utility
84Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 14, 1996 |
| Grant date | Nov 10, 1998 |
| Priority date | — |
| Expiry date | Aug 14, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T428/2985
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.